U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185841) titled 'Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)' on Sept. 15.
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Wet Age-related Macular Degeneration (AMD)
Intervention:
DRUG: HX9428 tablet
Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..
Recruitment Status: RECRUITING
Sponsor: Fujian Haixi Pharmaceuticals Co.,...